Redefining tumour suppressor genes: Exceptions to the two-hit hypothesis

Cellular and Molecular Life Sciences

Volumn 60, Issue 10, 2003, Pages 2147-2163

  Paige, A J W ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Cancer; Haploinsufficiency; Hypermethylation; Knudson two hit hypothesis; Tumour suppressor genes

Indexed keywords

APC PROTEIN; ATM PROTEIN; BRCA1 PROTEIN; BRCA2 PROTEIN; CYCLIN DEPENDENT KINASE; CYCLINE; MESSENGER RNA; PROTEIN P21; RAD51 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR SUPPRESSOR PROTEIN;

ALLELE; CANCER GENETICS; CANCER GROWTH; CELL CYCLE; DNA METHYLATION; FAMILIAL COLON POLYPOSIS; GENE LOCUS; HETEROZYGOSITY LOSS; HUMAN; HYPOTHESIS; KNUDSON TWO HIT HYPOTHESIS; NONHUMAN; POINT MUTATION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR SUPPRESSOR GENE; VARIABLE NUMBER OF TANDEM REPEAT;

ANIMALS; CELL CYCLE PROTEINS; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN-DEPENDENT KINASE INHIBITOR P27; GENES, TUMOR SUPPRESSOR; MICE; MICE, KNOCKOUT; PROTEIN ISOFORMS; TUMOR SUPPRESSOR PROTEINS;

EID: 0242351924     PISSN: 1420682X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00018-003-3027-6     Document Type: Review

References (134)

1. Ashley D. J. (1969) The two 'hit' and multiple 'hit' theories of carcinogenesis. Br. J. Cancer 23: 313-328
2. Knudson A. G. Jr (1971) Mutation and cancer: statistical study of retinoblastoma. Proc. Natl. Acad. Sci. USA 68: 820-823
3. Friend S. H., Bernards R., Rogelj S., Weinberg R. A., Rapaport J. M., Albert D. M. et al. (1986) A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 323: 643-646
4. Murphree A. L. and Benedict W. F. (1984) Retinoblastoma: clues to human oncogenesis. Science 223: 1028-1033
5. Knudson A. G. (1988) The genetics of childhood cancer. Bull. Cancer 75: 135-138
6. Knudson A. G. (1993) Antioncogenes and human cancer. Proc. Natl. Acad. Sci. USA 90: 10914-10921
7. Kinzler K. W. and Vogelstein B. (1997) Cancer-susceptibility genes. Gatekeepers and caretakers. Nature 386: 761, 763.
8. Hanahan D. and Weinberg R. A. (2000) The hallmarks of cancer. Cell 100: 57-70
9. Haber D. and Harlow E. (1997) Tumour-suppressor genes: evolving definitions in the genomic age. Nat. Genet. 16: 320-322
10. Ponder B. A. (2001) Cancer genetics. Nature 411: 336-341
11. Pietenpol J. A., Bohlander S. K., Sato Y., Papadopoulos N., Liu B., Friedman C. et al. (1995) Assignment of the human p27Kip1 gene to 12p13 and its analysis in leukemias. Cancer Res. 55: 1206-1210
12. Takeuchi S., Bartram C. R., Wada M., Reiter A., Hatta Y., Seriu T. et al. (1995) Allelotype analysis of childhood acute lymphoblastic leukemia. Cancer Res. 55: 5377-5382
13. Hatta Y., Takeuchi S., Yokota J. and Koeffler H. P. (1997) Ovarian cancer has frequent loss of heterozygosity at chromosome 12p12.3-13.1 (region of TEL and Kip1 loci) and chromosome 12q23-ter: evidence for two new tumour-suppressor genes. Br. J. Cancer 75: 1256-1262
14. Kibel A. S., Freije D., Isaacs W. B. and Bova G. S. (1999) Deletion mapping at 12p12-13 in metastatic prostate cancer. Genes Chromosomes Cancer 25: 270-276
15. Tsihlias J., Kapusta L. and Slingerland J. (1999) The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer. Annu. Rev. Med. 50: 401-423
16. Catzavelos C., Bhattacharya N., Ung Y. C., Wilson J. A., Roncari L., Sandhu C. et al. (1997) Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat. Med. 3: 227-230
17. Sgambato A., Ratto C., Faraglia B., Merico M., Ardito R., Schinzari G. et al. (1999) Reduced expression and altered subcellular localization of the cyclin-dependent kinase inhibitor p27(Kip1) in human colon cancer. Mol. Carcinog. 26: 172-179
18. Yasui W., Kudo Y., Semba S., Yokozaki H. and Tahara E. (1997) Reduced expression of cyclin-dependent kinase inhibitor p27Kip1 is associated with advanced stage and invasiveness of gastric carcinomas. Jpn. J. Cancer Res. 88: 625-629
19. Loda M., Cukor B., Tam S. W., Lavin P., Fiorentino M., Draetta G. F. et al. (1997) Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat. Med. 3: 231-234
20. Mori M., Mimori K., Shiraishi T., Tanaka S., Ueo H., Sugimachi K. et al. (1997) p27 expression and gastric carcinoma. Nat. Med. 3: 593
21. Newcomb E. W., Sosnow M., Demopoulos R. I., Zeleniuch-Jacquotte A., Sorich J. and Speyer J. L. (1999) Expression of the cell cycle inhibitor p27KIP1 is a new prognostic marker associated with survival in epithelial ovarian tumors. Am. J. Pathol. 154: 119-125
22. Cote R. J., Shi Y., Groshen S., Feng A. C., Cordon-Cardo C., Skinner D. et al. (1998) Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma. J. Natl. Cancer Inst. 90: 916-920
23. Del Pizzo J. J., Borkowski A., Jacobs S. C. and Kyprianou N. (1999) Loss of cell cycle regulators p27(Kip1) and cyclin E in transitional cell carcinoma of the bladder correlates with tumor grade and patient survival. Am. J. Pathol. 155: 1129-1136
24. Shamma A., Doki Y., Tsujinaka T., Shiozaki H., Inoue M., Yano M. et al. (2000) Loss of p27(KIP1) expression predicts poor prognosis in patients with esophageal squamous cell carcinoma. Oncology 58: 152-158
25. Spirin K. S., Simpson J. F., Takeuchi S., Kawamata N., Miller C. W. and Koeffler H. P. (1996) p27/Kip1 mutation found in breast cancer. Cancer Res. 56: 2400-2404
26. Morosetti R., Kawamata N., Gombart A. F., Miller C. W., Hatta Y., Hirama T. et al. (1995) Alterations of the p27KIP1 gene in non-Hodgkin's lymphomas and adult T-cell leukemia/lymphoma. Blood 86: 1924-1930
27. Fero M. L., Rivkin M., Tasch M., Porter P., Carow C. E., Firpo E. et al. (1996) A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis and female sterility in p27(Kip1)-deficient mice. Cell 85: 733-744
28. Fero M. L., Randel E., Gurley K. E., Roberts J. M. and Kemp C. J. (1998) The murine gene p27Kip1 is haplo-insufficient for tumour suppression. Nature 396: 177-180
29. Hirai H. and Sherr C. J. (1996) Interaction of D-type cyclins with a novel myb-like transcription factor, DMP1. Mol. Cell. Biol. 16: 6457-6467
30. Inoue K. and Sherr C. J. (1998) Gene expression and cell cycle arrest mediated by transcription factor DMP1 is antagonized by D-type cyclins through a cyclin-dependent-kinase-independent mechanism. Mol. Cell. Biol. 18: 1590-1600
31. Inoue K., Roussel M. F. and Sherr C. J. (1999) Induction of ARF tumor suppressor gene expression and cell cycle arrest by transcription factor DMP1. Proc. Natl. Acad. Sci. USA 96: 3993-3998
32. Inoue K., Wen R., Rehg J. E., Adachi M., Cleveland J. L., Roussel M. F. et al. (2000) Disruption of the ARF transcriptional activator DMP1 facilitates cell immortalization, Ras transformation, and tumorigenesis. Genes Dev 14: 1797-1809
33. Inoue K., Zindy F., Randle D. H., Rehg J. E. and Sherr C. J. (2001) Dmp1 is haplo-insufficient for tumor suppression and modifies the frequencies of Arf and p53 mutations in Myc-induced lymphomas. Genes Dev. 15: 2934-2939
34. Eischen C. M., Weber J. D., Roussel M. F., Sherr C. J. and Cleveland J. L. (1999) Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev. 13: 2658-2669
35. Barnes L. D., Garrison P. N., Siprashvili Z., Guranowski A., Robinson A. K., Ingram S. W. et al. (1996) Fhit, a putative tumor suppressor in humans, is a dinucleoside 5′,5‴-P1,P3-triphosphate hydrolase. Biochemistry 35: 11529-11535
36. Ohta M., Inoue H., Cotticelli M. G., Kastury K., Baffa R., Palazzo J. et al. (1996) The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell 84: 587-597
37. Sozzi G., Veronese M. L., Negrini M., Baffa R., Cotticelli M. G., Inoue H. et al. (1996) The FHIT gene 3p14.2 is abnormal in lung cancer. Cell 85: 17-26
38. Gayther S. A., Barski P., Batley S. J., Li L., de Foy K. A., Cohen S. N. et al. (1997) Aberrant splicing of the TSG101 and FHIT genes occurs frequently in multiple malignancies and in normal tissues and mimics alterations previously described in tumours. Oncogene 15: 2119-2126
39. Fong L. Y., Fidanza V, Zanesi N., Lock L. F., Siracusa L. D., Mancini R. et al. (2000) Muir-Torre-like syndrome in Fhit-deficient mice. Proc. Natl. Acad. Sci. USA 97: 4742-4747
40. Zanesi N., Fidanza V., Fong L. Y., Mancini R., Druck T., Valtieri M. et al. (2001) The tumor spectrum in FHIT-deficient mice. Proc. Natl. Acad. Sci. USA 98: 10250-10255
41. Dumon K. R., Ishii H., Fong L. Y., Zanesi N., Fidanza V, Mancini R. et al. (2001) FHIT gene therapy prevents tumor development in Fhit-deficient mice. Proc. Natl. Acad. Sci. USA 98: 3346-3351
42. Yan H., Dobbie Z., Gruber S. B., Markowitz S., Romans K., Giardiello F. M. et al. (2002) Small changes in expression affect predisposition to tumorigenesis. Nat. Genet. 30: 25-26
43. Fodde R. and Smits R. (2002) Cancer biology. A matter of dosage. Science 298: 761-763
44. Quon K. C. and Berns A. (2001) Haplo-insufficiency? Let me count the ways. Genes Dev. 15: 2917-2921
45. Swift M., Morrell D., Massey R. B. and Chase C. L. (1991) Incidence of cancer in 161 families affected by ataxia-telangiectasia. N. Engl. J. Med. 325: 1831-1836
46. Janin N., Andrieu N., Ossian K., Lauge A., Croquette M. F., Griscelli C. et al. (1999) Breast cancer risk in ataxia telangiectasia (AT) heterozygotes: haplotype study in French AT families. Br. J. Cancer 80: 1042-1045
47. Inskip H. M., Kinlen L. J., Taylor A. M., Woods C. G. and Arlett C. F. (1999) Risk of breast cancer and other cancers in heterozygotes for ataxia-telangiectasia. Br. J. Cancer 79: 1304-1307
48. Olsen J. H., Hahnemann J. M., Borresen-Dale A. L., Brondum-Nielsen K., Hammarstrom L., Kleinerman R. et al. (2001) Cancer in patients with ataxia-telangiectasia and in their relatives in the nordic countries. J. Natl. Cancer Inst. 93: 121-127
49. Geoffroy-Perez B., Janin N., Ossian K., Lauge A., Croquette M. F., Griscelli C. et al. (2001) Cancer risk in heterozygotes for ataxia- telangiectasia. Int. J. Cancer 93: 288-293
50. FitzGerald M. G., Bean J. M., Hegde S. R., Unsal H., MacDonald D. J., Harkin D. P. et al. (1997) Heterozygous ATM mutations do not contribute to early onset of breast cancer. Nat. Genet. 15:307-310
51. Izatt L., Greenman J., Hodgson S., Ellis D., Watts S., Scott G. et al. (1999) Identification of germline missense mutations and rare allelic variants in the ATM gene in early-onset breast cancer. Genes Chromosomes Cancer 26: 286-294
52. Teraoka S. N., Malone K. E., Doody D. R., Suter N. M., Ostrander E. A., Daling J. R. et al. (2001) Increased frequency of ATM mutations in breast carcinoma patients with early onset disease and positive family history. Cancer 92: 479-487
53. Dork T., Bendix R., Bremer M., Rades D., Klopper K., Nicke M. et al. (2001) Spectrum of ATM gene mutations in a hospital-based series of unselected breast cancer patients. Cancer Res. 61: 7608-7615
54. Scott S. P., Bendix R., Chen R, Clark R., Dork T. and Lavin M. F. (2002) Missense mutations but not allelic variants alter the function of ATM by dominant interference in patients with breast cancer. Proc. Natl. Acad. Sci. USA 99: 925-930
55. Spring K., Ahangari F., Scott S. P., Waring R, Purdie D. M., Chen P. C. et al. (2002) Mice heterozygous for mutation in Atm, the gene involved in ataxia-telangiectasia, have heightened susceptibility to cancer. Nat. Genet. 32: 185-190
56. Sager R., Sheng S., Anisowicz A., Sotiropoulou G., Zou Z., Stenman G. et al. (1994) RNA genetics of breast cancer: maspin as paradigm. Cold Spring Harb. Symp. Quant. Biol. 59: 537-546
57. Zhang W., Razani B., Altschuler Y., Bouzahzah B., Mostov K. E., Pestell R. G. et al. (2000) Caveolin-1 inhibits epidermal growth factor-stimulated lamellipod extension and cell migration in metastatic mammary adenocarcinoma cells (MTLn3). Transformation suppressor effects of adenovirus-mediated gene delivery of caveolin-1. J. Biol. Chem. 275: 20717-20725
58. Lee S. W., Reimer C. L., Oh P., Campbell D. B. and Schnitzer J. E. (1998) Tumor cell growth inhibition by caveolin re-expression in human breast cancer cells. Oncogene 16: 1391-1397
59. Galbiati F., Volonte D., Engelman J. A., Watanabe G., Burk R., Pestell R. G. et al. (1998) Targeted downregulation of caveolin-1 is sufficient to drive cell transformation and hyperactivate the p42/44 MAP kinase cascade. EMBO J. 17: 6633-6648
60. Hayashi K., Matsuda S., Machida K., Yamamoto T., Fukuda Y., Nimura Y. et al. (2001) Invasion activating caveolin-1 mutation in human scirrhous breast cancers. Cancer Res. 61: 2361-2364
61. Lee H., Park D. S., Razani B., Russell R. G., Pestell R. G. and Lisanti M. P. (2002) Caveolin-1 mutations (P132L and null) and the pathogenesis of breast cancer: caveolin-1 (P132L) behaves in a dominant-negative manner and caveolin-1 (-/-) null mice show mammary epithelial cell hyperplasia. Am. J. Pathol. 161: 1357-1369
62. Gualberto A., Aldape K., Kozakiewicz K. and Tlsty T. D. (1998) An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control. Proc. Natl. Acad. Sci. USA 95: 5166-5171
63. Blandino G., Levine A. J. and Oren M. (1999) Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 18: 477-485
64. Pugacheva E. N., Ivanov A. V., Kravchenko J. E., Kopnin B. P., Levine A. J. and Chumakov P. M. (2002) Novel gain of function activity of p53 mutants: activation of the dUTPase gene expression leading to resistance to 5-fluorouracil. Oncogene 21: 4595-4600
65. Knudson A. G. (2001) Two genetic hits (more or less) to cancer. Nat. Rev. Cancer 1: 157-162
66. Fearon E. R. and Vogelstein B. (1990) A genetic model for colorectal tumorigenesis. Cell 61: 759-767
67. Groden J., Thliveris A., Samowitz W., Carlson M., Gelbert L., Albertsen H. et al. (1991) Identification and characterization of the familial adenomatous polyposis coli gene. Cell 66: 589-600
68. Kikuchi-Yanoshita R., Konishi M., Ito S., Seki M., Tanaka K., Maeda Y. et al. (1992) Genetic changes of both p53 alleles associated with the conversion from colorectal adenoma to early carcinoma in familial adenomatous polyposis and non-familial adenomatous polyposis patients. Cancer Res. 52: 3965-3971
69. Consortium B. C. L. (1997) Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium. Lancet 349: 1505-1510
70. Levy-Lahad E., Lahad A., Eisenberg S., Dagan E., Paperna T., Kasinetz L. et al. (2001) A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers. Proc. Natl. Acad. Sci. USA 98: 3232-3236
71. Wang W. W., Spurdle A. B., Kolachana P., Bove B., Modan B., Ebbers S. M. et al. (2001) A single nucleotide polymorphism in the 5′ untranslated region of RAD51 and risk of cancer among BRCA1/2 mutation carriers. Cancer Epidemiol. Biomarkers Prev. 10: 955-960
72. Rebbeck T. R., Kantoff P. W., Krithivas K., Neuhausen S., Blackwood M. A., Godwin A. K. et al. (1999) Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat. Am. J. Hum. Genet. 64: 1371-1377
73. Phelan C. M., Rebbeck T. R., Weber B. L., Devilee P., Ruttledge M. H., Lynch H. T. et al. (1996) Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus. Nat. Genet. 12: 309-311
74. Dietrich W. F., Lander E. S., Smith J. S., Moser A. R., Gould K. A., Luongo C. et al. (1993) Genetic identification of Mom-1, a major modifier locus affecting Min-induced intestinal neoplasia in the mouse. Cell 75: 631-639
75. Cormier R. T., Bilger A., Lillich A. J., Halberg R. B., Hong K. H., Gould K. A. et al. (2000) The Mom1 AKR intestinal tumor resistance region consists of Pla2g2a and a locus distal to D4Mit64. Oncogene 19: 3182-3192
76. Gould K. A., Luongo C., Moser A. R., McNeley M. K., Borenstein N., Shedlovsky A. et al. (1996) Genetic evaluation of candidate genes for the Mom1 modifier of intestinal neoplasia in mice. Genetics 144: 1777-1785
77. MacPhee M., Chepenik K. P., Liddell R. A., Nelson K. K., Siracusa L. D. and Buchberg A. M. (1995) The secretory phospholipase A2 gene is a candidate for the Mom1 locus, a major modifier of ApcMin-induced intestinal neoplasia. Cell 81: 957-966
78. Kennedy B. P., Payette P., Mudgett J., Vadas P., Pruzanski W., Kwan M. et al. (1995) A natural disruption of the secretory group II phospholipase A2 gene in inbred mouse strains. J. Biol. Chem. 270: 22378-22385
79. Oshima M., Dinchuk J. E., Kargman S. L., Oshima H., Hancock B., Kwong E. et al. (1996) Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87: 803-809
80. Takaku K., Sonoshita M., Sasaki N., Uozumi N., Doi Y., Shimizu T. et al. (2000) Suppression of intestinal polyposis in Apc(delta 716) knockout mice by an additional mutation in the cytosolic phospholipase A(2) gene. J. Biol. Chem. 275: 34013-34016
81. Hong K. H., Bonventre J. C., O'Leary E., Bonventre J. V. and Lander E. S. (2001) Deletion of cytosolic phospholipase A(2) suppresses Apc(Min)-induced tumorigenesis. Proc. Natl. Acad. Sci. USA 98: 3935-3939
82. Riggins G. J., Markowitz S., Wilson J. K., Vogelstein B. and Kinzler K. W. (1995) Absence of secretory phospholipase A2 gene alterations in human colorectal cancer. Cancer Res. 55: 5184-5186
83. Nimmrich I., Friedl W., Kruse R., Pietsch S., Hentsch S., Deuter R. et al. (1997) Loss of the PLA2G2A gene in a sporadic colorectal tumor of a patient with a PLA2G2A germline mutation and absence of PLA2G2A germline alterations in patients with FAP. Hum. Genet. 100: 345-349
84. Praml C., Amler L. C., Dihlmann S., Finke L. H., Schlag P. and Schwab M. (1998) Secretory type II phospholipase A2 (PLA2G2A) expression status in colorectal carcinoma derived cell lines and in normal colonie mucosa. Oncogene 17: 2009-2012
85. Dobbie Z., Heinimann K., Bishop D. T., Muller H. and Scott R. J. (1997) Identification of a modifier gene locus on chromosome 1p35-36 in familial adenomatous polyposis. Hum. Genet. 99: 653-657
86. Crabtree M. D., Tomlinson I. P., Hodgson S. V., Neale K., Phillips R. K. and Houlston R. S. (2002) Explaining variation in familial adenomatous polyposis: relationship between genotype and phenotype and evidence for modifier genes. Gut 51: 420-423
87. Spirio L. N., Kutchera W., Winstead M. V., Pearson B., Kaplan C., Robertson M. et al. (1996) Three secretory phospholipase A(2) genes that map to human chromosome 1P35-36 are not mutated in individuals with attenuated adenomatous polyposis coli. Cancer Res. 56: 955-958
88. Dobbie Z., Muller H. and Scott R. J. (1996) Secretory phospholipase A2 does not appear to be associated with phenotypic variation in familial adenomatous polyposis. Hum. Genet. 98: 386-390
89. Leung S. Y., Chen X., Chu K. M., Yuen S. T., Mathy J., Ji J. et al. (2002) Phospholipase A2 group IIA expression in gastric adenocarcinoma is associated with prolonged survival and less frequent metastasis. Proc. Natl. Acad. Sci. USA 99: 16203-16208
90. Risinger J. I., Berchuck A., Kohler M. F., Watson P., Lynch H. T. and Boyd J. (1993) Genetic instability of microsatellites in endometrial carcinoma. Cancer Res. 53: 5100-5103
91. Ionov Y., Peinado M. A., Malkhosyan S., Shibata D. and Perucho M. (1993) Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonie carcinogenesis. Nature 363: 558-561
92. Maliaka Y. K., Chudina A. P., Belev N. F., Alday P., Bochkov N. P. and Buerstedde J. M. (1996) CpG dinucleotides in the hMSH2 and hMLH1 genes are hotspots for HNPCC mutations. Hum. Genet. 97: 251-255
93. Akiyama Y., Sato H., Yamada T., Nagasaki H., Tsuchiya A., Abe R. et al. (1997) Germ-line mutation of the hMSH6/GTBP gene in an atypical hereditary nonpolyposis colorectal cancer kindred. Cancer Res. 57: 3920-3923
94. Nicolaides N. C., Papadopoulos N., Liu B., Wei Y. F., Carter K. C., Ruben S. M. et al. (1994) Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. Nature 371: 75-80
95. Percesepe A., Pedroni M., Sala E., Menigatti M., Borghi F., Losi L. et al. (2000) Genomic instability and target gene mutations in colon cancers with different degrees of allelic shifts. Genes Chromosomes Cancer 27: 424-429
96. Furlan D., Casati B., Cerutti R., Facco C., Terracciano L., Capella C. et al. (2002) Genetic progression in sporadic endometrial and gastrointestinal cancers with high microsatellite instability. J. Pathol. 197: 603-609
97. Calin G. A., Gafa R., Tibiletti M. G., Herlea V., Becheanu G., Cavazzini L. et al. (2000) Genetic progression in microsatellite instability high (MSI-H) colon cancers correlates with clinico-pathological parameters: a study of the TGRbetaRII, BAX, hMSH3, hMSH6, IGFIIR and BLM genes. Int. J. Cancer 89: 230-235
98. Menoyo A., Alazzouzi H., Espin E., Armengol M., Yamamoto H. and Schwartz S. Jr (2001) Somatic mutations in the DNA damage-response genes ATR and CHK1 in sporadic stomach tumors with microsatellite instability. Cancer Res. 61: 7727-7730
99. Akiyama Y., Iwanaga R., Saitoh K., Shiba K., Ushio K., Ikeda E. et al. (1997) Transforming growth factor beta type II receptor gene mutations in adenomas from hereditary nonpolyposis colorectal cancer. Gastroenterology 112: 33-39
100. Yagi O. K., Akiyama Y., Nomizu T., Iwama T., Endo M. and Yuasa Y. (1998) Proapoptotic gene BAX is frequently mutated in hereditary nonpolyposis colorectal cancers but not in adenomas. Gastroenterology 114: 268-274
101. Prime S. S., Thakker N. S., Pring M., Guest P. G. and Paterson I. C. (2001) A review of inherited cancer syndromes and their relevance to oral squamous cell carcinoma. Oral Oncol. 37: 1-16
102. Bogliolo M., Cabre O., Callen E., Castillo V., Creus A., Marcos R. et al. (2002) The Fanconi anaemia genome stability and tumour suppressor network. Mutagenesis 17: 529-538
103. Gruber S. B., Ellis N. A., Scott K. K., Almog R., Kolachana P., Bonner J. D. et al. (2002) BLM heterozygosity and the risk of colorectal cancer. Science 297: 2013
104. Goss K. H., Risinger M. A., Kordich J. I., Sanz M. M., Straughen J. E., Slovek L. E. et al. (2002) Enhanced tumor formation in mice heterozygous for Blm mutation. Science 297: 2051-2053
105. Derynck R., Akhurst R. J. and Balmain A. (2001) TGF-beta signaling in tumor suppression and cancer progression. Nat. Genet. 29: 117-129
106. Engle S. J., Hoying J. B., Boivin G. P., Ormsby I., Gartside P. S. and Doetschman T. (1999) Transforming growth factor betal suppresses nonmetastatic colon cancer at an early stage of tumorigenesis. Cancer Res. 59: 3379-3386
107. Markowitz S., Wang J., Myeroff L., Parsons R., Sun L., Lutterbaugh J. et al. (1995) Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 268: 1336-1338
108. Myeroff L. L., Parsons R., Kim S. J., Hedrick L., Cho K. R., Orth K. et al. (1995) A transforming growth factor beta receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability. Cancer Res. 55: 5545-5547
109. Chen T., Triplett J., Dehner B., Hurst B., Colligan B., Pemberton J. et al. (2001) Transforming growth factor-beta receptor type I gene is frequently mutated in ovarian carcinomas. Cancer Res. 61: 4679-4682
110. Miyaki M., Iijima T., Konishi M., Sakai K., Ishii A., Yasuno M. et al. (1999) Higher frequency of Smad4 gene mutation in human colorectal cancer with distant metastasis. Oncogene 18: 3098-3103
111. Eppert K., Scherer S. W., Ozcelik H., Pirone R., Hoodless P., Kim H. et al. (1996) MADR2 maps to 18q21 and encodes a TGFbeta-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell 86: 543-552
112. Sun L., Wu G., Willson J. K., Zborowska E., Yang J., Rajkarunanayake I. et al. (1994) Expression of transforming growth factor beta type II receptor leads to reduced malignancy in human breast cancer MCF-7 cells. J. Biol. Chem. 269: 26449-26455
113. Derynck R., Goeddel D. V., Ullrich A., Gutterman J. U., Williams R. D., Bringman T. S. et al. (1987) Synthesis of messenger RNAs for transforming growth factors alpha and beta and the epidermal growth factor receptor by human tumors. Cancer Res. 47: 707-712
114. Dickson R. B., Kasid A., Huff K. K., Bates S. E., Knabbe C., Bronzert D. et al. (1987) Activation of growth factor secretion in tumorigenic states of breast cancer induced by 17 beta-estradiol or v-Ha-ras oncogene. Proc. Natl. Acad. Sci. USA 84: 837-841.
115. Cui W., Fowlis D. J., Bryson S., Duffie E., Ireland H., Balmain A. et al. (1996) TGFbeta1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell 86: 531-542
116. Oft M., Heider K. H. and Beug H. (1998) TGFbeta signaling is necessary for carcinoma cell invasiveness and metastasis. Curr. Biol. 8: 1243-1252
117. Capo-Chichi C. D., Smith E. R., Yang D. H., Roland I. H., Vanderveer L., Cohen C. et al. (2002) Dynamic alterations of the extracellular environment of ovarian surface epithelial cells in premalignant transformation, tumorigenicity and metastasis. Cancer 95: 1802-1815
118. Fung Y. K., Murphree A. L., T'Ang A., Qian J., Hinrichs S. H. and Benedict W. F. (1987) Structural evidence for the authenticity of the human retinoblastoma gene. Science 236: 1657-1661
119. Hensel C. H., Hsieh C. L., Gazdar A. F., Johnson B. E., Sakaguchi A. Y., Naylor S. L. et al. (1990) Altered structure and expression of the human retinoblastoma susceptibility gene in small cell lung cancer. Cancer Res. 50: 3067-3072
120. Hagstrom S. A. and Dryja T. P. (1999) Mitotic recombination map of 13cen-13q14 derived from an investigation of loss of heterozygosity in retinoblastomas. Proc. Natl. Acad. Sci. USA 96: 2952-2957
121. Choy K. W., Pang C. P., Yu C. B., Wong H. L., Ng J. S., Fan D. S. et al. (2002) Loss of heterozygosity and mutations are the major mechanisms of RB1 gene inactivation in Chinese with sporadic retinoblastoma. Hum. Mutat. 20: 408
122. Kamb A., Gruis N. A., Weaver-Feldhaus J., Liu Q., Harshman K., Tavtigian S. V. et al. (1994) A cell cycle regulator potentially involved in genesis of many tumor types. Science 264: 436-440
123. Merlo A., Herman J. G., Mao L., Lee D. J., Gabrielson E., Burger P. C. et al. (1995) 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat. Med. 1: 686-692
124. Lee Y. Y., Kang S. H., Seo J. Y., Jung C. W., Lee K. U., Choe K. J. et al. (1997) Alterations of p16INK4A and p15INK4B genes in gastric carcinomas. Cancer 80: 1889-1896
125. Shim Y. H., Kang G. H. and Ro J. Y. (2000) Correlation of p16 hypermethylation with pi 6 protein loss in sporadic gastric carcinomas. Lab. Invest. 80: 689-695
126. Jones P. A. and Laird P. W. (1999) Cancer epigenetics comes of age. Nat. Genet. 21: 163-167
127. Li Q. L., Ito K., Sakakura C., Fukamachi H., Inoue K., Chi X. Z. et al. (2002) Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 109: 113-124
128. Balmain A. (2002) Cancer: new-age tumour suppressors. Nature 417: 235-237
129. Bednarek A. K., Laflin K. J., Daniel R. L., Liao Q., Hawkins K. A. and Aldaz C. M. (2000) WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer. Cancer Res. 60: 2140-2145
130. Paige A. J., TaylorK. J., Taylor C., Hillier S. G., Farrington S., Scott D. et al. (2001) WWOX: a candidate tumor suppressor gene involved in multiple tumor types. Proc. Natl. Acad. Sci. USA 98: 11417-11422
131. Ried K., Finnis M., Hobson L., Mangelsdorf M., Dayan S., Nancarrow J. K. et al. (2000) Common chromosomal fragile site FRA16D sequence: identification of the FOR gene spanning FRA16D and homozygous deletions and translocation breakpoints in cancer cells. Hum. Mol. Genet. 9: 1651-1663
132. Kuroki T., Trapasso F., Shiraishi T., Alder H., Mimori K., Mori M. et al. (2002) Genetic alterations of the tumor suppressor gene WWOX in esophageal squamous cell carcinoma. Cancer Res. 62: 2258-2260
133. Bednarek A. K., Keck-Waggoner C. L., Daniel R. L., Laflin K. J., Bergsagel P. L., Kiguchi K. et al. (2001) WWOX, the FRA16D gene, behaves as a suppressor of tumor growth. Cancer Res. 61: 8068-8073
134. Chang N. S., Pratt N., Heath J., Schultz L., Sleve D., Carey G. B. et al. (2001) Hyaluronidase induction of a WW domain-containing oxidoreductase that enhances tumor necrosis factor cytotoxicity. J. Biol. Chem. 276: 3361-3370